Upside gappers:
In reaction to strong earnings/guidance: SYNC +7.3%, (reaffirms Q3 guidance; raises FY14 EBITDA guidance; revises strategic plan)
M&A news: ANGI +20.7% (FT reports co hired bankers to explore alternatives, including sale), AKRX +1.3% (acquires Xopenenx Inhalation Soplutions for approx $45 mln in cash; expects this transaction to add ~$18 million to $20 million in revenues and approximately $0.07 to $0.08 of net income per diluted share in 2015)
Select Ebola related names showing strength after CDC confirmed ebola case diagnosed in the US: TKMR +26.8%, HEB +21.9%, LAKE +12.2%, NNVC +10%, NLNK +9.5%, BCRX +8.4%, SRPT +6.6%, INO +5.1%.
Other news: MTL +16.8% (extending yesterday's gains boosted by positive VTB comments), CGEN +5.1% (discloses new results for novel target candidate for cancer immunotherapy; recent data further support CGEN-15049 immune checkpoint role in inhibiting the immune response to cancer cells), RTRX +3.1% (still checking), APP +2.4% (may keep Dov Charney on Board, according to reports), KERX +1.5% (announces issuance of a new U.S. patent for ferric citrate covering orally administrable forms), VE +1.2% (still checking), WAG +1.2% (Express Scripts collaborates with Walgreens (WAG) to create Medicare Prescription Drug Plan pharmacy network), BBRY +1.2% (still checking), .
Analyst comments: AGN +2.1% (upgraded to Buy at Stifel), DYN +1.9% (upgraded to Buy from Neutral at ISI Group), OWW +1.9% (upgraded to Outperform at Oppenheimer), JNS +1.4% (upgraded to Buy from Hold at Jefferies)
Market Data 
Markets 
AI
